University College London 
Welcome,         Profile    Billing    Logout  
 4 Products   0 Diseases  4 Products   5 Trials   38 News 
15 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tgAAG76 / Armata, University College London
2006-001571-37: AN OPEN-LABEL DOSE ESCALATION STUDY OF AN ADENO-ASSOCIATED VIRUS VECTOR (AAV2/2-hRPE65p-hRPE65) FOR GENE THERAPY OF SEVERE EARLY-ONSET RETINAL DEGENERATION

Ongoing
2
12
Europe
tgAAG76,
University College London
The condition to be investigated is severe early-onset inherited retinal degeneration due to defects in the gene encoding RPE65
 
 
PF-05206388 / University College London, Pfizer
NCT01691261: A Study of Implantation of Retinal Pigment Epithelium in Subjects with Acute Wet Age Related Macular Degeneration

Completed
1
9
Europe
PF-05206388
Moorfields Eye Hospital NHS Foundation Trust, University College, London
Age Related Macular Degeneration
10/23
06/24
NCT03102138: Retinal Pigment Epithelium Safety Study for Patients in B4711001

Active, not recruiting
N/A
10
Europe
Moorfields Eye Hospital NHS Foundation Trust
Age Related Macular Degeneration
05/27
06/28
E2814 / Eisai, University College London
DIAN-TU, NCT05269394: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Active, not recruiting
2/3
197
Europe, Canada, Japan, US, RoW
E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Alzheimer's Association, National Institute on Aging (NIA), Accelerating Medicines Partnership (AMP), Eisai Inc.
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
04/28
07/28
DIAN-TU, NCT01760005 / 2013-000307-17: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol -001

Checkmark From DIAN-TU trial
Feb 2020 - Feb 2020: From DIAN-TU trial
Checkmark Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Feb 2020 - Feb 2020: Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Checkmark DIAN TU: N=210
More
Recruiting
2/3
490
Europe, Canada, Japan, US, RoW
Gantenerumab, RO4909832, Solanezumab, LY2062430, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Eli Lilly and Company, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA), Avid Radiopharmaceuticals, Accelerating Medicines Partnership (AMP), Eisai Inc., Janssen, LP
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
04/28
07/28
NCT06602258: A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

Active, not recruiting
2
105
Japan, US
E2814, Lecanemab, BAN2401, LEQEMBI, Placebo
Eisai Inc.
Alzheimer's Disease
06/26
08/27
NCT03852277: A Study to Assess Safety, Tolerability, Pharmacodynamics, Immunogenicity, Exploratory Clinical Efficacy, and Pharmacokinetics of Intravenous Infusions of E2814 in Healthy Participants and Participants With Prodromal Alzheimer's Disease (AD) to Moderate AD With and Without Detectable Tau Pathology

Not yet recruiting
1/2
275
US
E2814, E2814-matched placebo
Eisai Inc.
Healthy Volunteers, Alzheimer Disease, Dementia
02/23
02/23
NCT04971733: A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

Completed
1/2
8
Europe, US
E2814
Eisai Inc.
Alzheimer Disease
05/24
05/24
NCT04231513: A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants

Completed
1
72
US
E2814, E2814-matched placebo
Eisai Inc.
Healthy Volunteers
03/23
03/23
cevaretigene ritoparvovec (AAV2-RPE65) / Medical Research Council, MeiraGTx, University College London
NCT02946879 / 2016-000898-20: Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)

Completed
1/2
15
Europe, US
AAV OPTIRPE65
MeiraGTx UK II Ltd, Syne Qua Non Limited
Leber Congenital Amaurosis (LCA), Eye Diseases, Eye Diseases, Hereditary, Retinal Diseases
07/23
07/23
2015-003418-25: Gene Therapy Trial for LCA2 OPTIRPE65

Ongoing
1
27
Europe
AAV2/5-OPTIRPE65, Solution for injection
MeiraGTx UK II Ltd, Medical Research Council, MeiraGTx UK II Ltd
Leber Congenital Amaurosis (LCA) caused by mutations in RPE65, Retinal degeneration caused by mutations in RPE65, Diseases [C] - Eye Diseases [C11]
 
 
KCAT19 T cells / University College London
KCAT19, NCT05391490: Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies

Not yet recruiting
1
12
NA
KCAT19 T cells
University College, London
Blood Cancer
11/24
11/34
GD2 CAR T / University College London, Great Ormond Street Hospital for Children
CARMIGO, NCT05544526: CAR T Cells to Target GD2 for DMG

Recruiting
1
12
Europe
GD2 CAR T cells
University College, London
Diffuse Midline Glioma, H3 K27M-Mutant
12/25
12/39
MAGNETO, NCT05990751: Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma

Recruiting
1
12
Europe
GD2 CAR T cells
University College, London
Neuroblastoma
12/26
12/41
BCMA CAR T cells / University College London
MCARTY, NCT04795882: A New Study Evaluating the Activity of Modular CAR T for mYeloma

Active, not recruiting
1
24
Europe
BCMA CAR T cells, BCMA/CD19 CAR T cells
University College, London
Multiple Myeloma
12/25
12/35
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tgAAG76 / Armata, University College London
2006-001571-37: AN OPEN-LABEL DOSE ESCALATION STUDY OF AN ADENO-ASSOCIATED VIRUS VECTOR (AAV2/2-hRPE65p-hRPE65) FOR GENE THERAPY OF SEVERE EARLY-ONSET RETINAL DEGENERATION

Ongoing
2
12
Europe
tgAAG76,
University College London
The condition to be investigated is severe early-onset inherited retinal degeneration due to defects in the gene encoding RPE65
 
 
PF-05206388 / University College London, Pfizer
NCT01691261: A Study of Implantation of Retinal Pigment Epithelium in Subjects with Acute Wet Age Related Macular Degeneration

Completed
1
9
Europe
PF-05206388
Moorfields Eye Hospital NHS Foundation Trust, University College, London
Age Related Macular Degeneration
10/23
06/24
NCT03102138: Retinal Pigment Epithelium Safety Study for Patients in B4711001

Active, not recruiting
N/A
10
Europe
Moorfields Eye Hospital NHS Foundation Trust
Age Related Macular Degeneration
05/27
06/28
E2814 / Eisai, University College London
DIAN-TU, NCT05269394: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Active, not recruiting
2/3
197
Europe, Canada, Japan, US, RoW
E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Alzheimer's Association, National Institute on Aging (NIA), Accelerating Medicines Partnership (AMP), Eisai Inc.
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
04/28
07/28
DIAN-TU, NCT01760005 / 2013-000307-17: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol -001

Checkmark From DIAN-TU trial
Feb 2020 - Feb 2020: From DIAN-TU trial
Checkmark Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Feb 2020 - Feb 2020: Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Checkmark DIAN TU: N=210
More
Recruiting
2/3
490
Europe, Canada, Japan, US, RoW
Gantenerumab, RO4909832, Solanezumab, LY2062430, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Eli Lilly and Company, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA), Avid Radiopharmaceuticals, Accelerating Medicines Partnership (AMP), Eisai Inc., Janssen, LP
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
04/28
07/28
NCT06602258: A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

Active, not recruiting
2
105
Japan, US
E2814, Lecanemab, BAN2401, LEQEMBI, Placebo
Eisai Inc.
Alzheimer's Disease
06/26
08/27
NCT03852277: A Study to Assess Safety, Tolerability, Pharmacodynamics, Immunogenicity, Exploratory Clinical Efficacy, and Pharmacokinetics of Intravenous Infusions of E2814 in Healthy Participants and Participants With Prodromal Alzheimer's Disease (AD) to Moderate AD With and Without Detectable Tau Pathology

Not yet recruiting
1/2
275
US
E2814, E2814-matched placebo
Eisai Inc.
Healthy Volunteers, Alzheimer Disease, Dementia
02/23
02/23
NCT04971733: A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

Completed
1/2
8
Europe, US
E2814
Eisai Inc.
Alzheimer Disease
05/24
05/24
NCT04231513: A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants

Completed
1
72
US
E2814, E2814-matched placebo
Eisai Inc.
Healthy Volunteers
03/23
03/23
cevaretigene ritoparvovec (AAV2-RPE65) / Medical Research Council, MeiraGTx, University College London
NCT02946879 / 2016-000898-20: Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)

Completed
1/2
15
Europe, US
AAV OPTIRPE65
MeiraGTx UK II Ltd, Syne Qua Non Limited
Leber Congenital Amaurosis (LCA), Eye Diseases, Eye Diseases, Hereditary, Retinal Diseases
07/23
07/23
2015-003418-25: Gene Therapy Trial for LCA2 OPTIRPE65

Ongoing
1
27
Europe
AAV2/5-OPTIRPE65, Solution for injection
MeiraGTx UK II Ltd, Medical Research Council, MeiraGTx UK II Ltd
Leber Congenital Amaurosis (LCA) caused by mutations in RPE65, Retinal degeneration caused by mutations in RPE65, Diseases [C] - Eye Diseases [C11]
 
 
KCAT19 T cells / University College London
KCAT19, NCT05391490: Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies

Not yet recruiting
1
12
NA
KCAT19 T cells
University College, London
Blood Cancer
11/24
11/34
GD2 CAR T / University College London, Great Ormond Street Hospital for Children
CARMIGO, NCT05544526: CAR T Cells to Target GD2 for DMG

Recruiting
1
12
Europe
GD2 CAR T cells
University College, London
Diffuse Midline Glioma, H3 K27M-Mutant
12/25
12/39
MAGNETO, NCT05990751: Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma

Recruiting
1
12
Europe
GD2 CAR T cells
University College, London
Neuroblastoma
12/26
12/41
BCMA CAR T cells / University College London
MCARTY, NCT04795882: A New Study Evaluating the Activity of Modular CAR T for mYeloma

Active, not recruiting
1
24
Europe
BCMA CAR T cells, BCMA/CD19 CAR T cells
University College, London
Multiple Myeloma
12/25
12/35

Download Options